The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease

Current Cardiology Reports

Volumn 4, Issue 4, 2002, Pages 278-288

  Zebrack, James S ^a   Anderson, Jeffrey L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; HUMAN; INFECTION; INFLAMMATION; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR;

ANIMALS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; INFECTION; INFLAMMATION; PREVALENCE; RISK FACTORS;

EID: 0036655107     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0063-z     Document Type: Article

References (50)

1. Libby P: Molecular basis of the acute coronary syndromes. Circulation 1995, 91:2844.
2. Libby P, Egan D, Skarlatos S: Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997, 96:4095-103.
3. Epstein SE, Zhou YF, Zhu J: Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999, 100:e20-e28.
4. Anderson JL, Muhlestein JB: Pathophysiology: infection. In Acute Coronary Syndromes: A Companion to Braunwald's Textbook of Cardiovascular Medicine. Edited by Theroux P, Braunwald E. Philadelphia: W B Saunders; 2002: in press.
5. Valen G, Yan ZQ, Hansson GK: Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001, 38:307-314.
6. Ley K, Huo Y: VCAM-1 is critical in atherosclerosis. J Clin Invest 2001, 107:1209-1210.
7. Mach F, Schonbeck U, Libby P: CD40 signaling in vascular cells: a key role in atherosclerosis. Atherosclerosis 1998, 137:S89-S95.
8. Nakajima T, Schulte S, Warrington KJ, et al.: T-cell lysis of endothelial cells in acute coronary syndromes. Circulation 2002, 105:570-575.
9. Smith SC Jr., Greenland P, Grundy SM: Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Executive summary. Circulation 2000, 101:111-116.
10. Rader DJ: Inflammatory markers of coronary risk. N Engl J Med 2000, 343:1179-1182.
11. Ridker PM: Novel risk factors and markers for coronary disease. Adv Intern Med 2000, 45:391-418.
12. Volpato S, Guralnik JM, Ferrucci L, et al.: Cardiovascular disease, interleukin-6, and risk of mortality in older women. Circulation 2001, 103:947-953.
13. Blankenberg S, Rupprecht HJ, Bickel C, et al.: Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation 2001, 103:2915-2921.
14. Koenig W: Fibrinogen and coronary risk. Curr Cardiol Rep 1999, 1:112-118.
15. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279:1477-1482.
16. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C- reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001, 285:2481-2485.
17. Ridker PM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813-1818.
18. Wolbink GJ, Brouwer MC, Buysmann S, et al.: CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996, 157:473-479.
19. Szalai AJ, VanCott JL, McGhee JR, et al.: Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun 2000, 68:5652-5656.
20. Yasojima K, Schwab C, McGeer EG, McGeer PL: Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001, 158:1039-1051.
21. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
22. Torzewski M, Rist C, Mortensen RF, et al.: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20:2094-2099.
23. Pasceri V, Chang J, Willerson JT, Yeh ET: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103:2531-2534.
24. Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103:1194-1197.
25. Griselli M, Herbert J, Hutchinson WL, et al.: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999, 190:1733-1740.
26. Lagrand WK, Niessen HW, Wolbink GJ, et al.: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997, 95:97-103.
27. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
28. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
29. Grayston JT: Infections caused by Cpn strain TWAR. Clin Infect Dis 1992, 15:757-761.
30. Byrne GI, Kalayoglu MV: Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J 1999, 138:S488-S490.
31. Moazed TC, Campbell LA, Rosenfeld ME, et al.: Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999, 180:238-241.
32. Muhlestein JB, Anderson JL, Hammond EH, et al.: Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998, 97:633-636.
33. Muhlestein JB, Hammond EH, Carlquist JF, et al.: Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996, 27:1555-1561.
34. Ericson K, Saldeen TG, Lindquist O, et al.: Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. Circulation 2000, 101:2568-2571.
35. Danesh J: Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies. Am Heart J 1999, 138:S434-S437.
36. Siscovick DS, Schwartz SM, Corey L, et al.: Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study. Circulation 2000, 102:2335-2340.
37. Neumann F, Kastrati A, Miethke T, et al.: Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR- 3): a randomised, double-blind, placebo-controlled trial. Lancet 2001, 357:2085-2089.
38. Muhlestein JB, Anderson JL, Carlquist JF, et al.: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000, 102:1755-1760.
39. Nieto FJ: Viruses and atherosclerosis: a critical review of the epidemiologic evidence. Am Heart J 1999, 138:S453-S460.
40. Muhlestein JB, Horne BD, Carlquist JF, et al.: Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000, 102:1917-1923.
41. Alber DG, Powell KL, Vallance P, et al.: Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation 2000, 102:779-785.
42. Chiu B: Multiple infections in carotid atherosclerotic plaques. Am Heart J 1999, 138:S534-S536.
43. Roivainen M, Viik-Kajander M, Palosuo T, et al.: Infections, inflammation, and the risk of coronary heart disease. Circulation 2000, 101:252-257.
44. Naghavi M, Barlas Z, Siadaty S, et al.: Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000, 102:3039-3045.
45. Kiechl S, Egger G, Mayr M, et al.: Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001, 103:1064-1070.
46. Howell TH, Ridker PM, Ajani UA, et al.: Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol 2001, 37:445-450.
47. Zhu J, Quyyumi AA, Norman JE, et al.: Effects of total pathogen burden on coronary artery disease risk and C- reactive protein levels. Am J Cardiol 2000, 85:140-146.
48. Zhu J, Nieto FJ, Horne BD, et al.: Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001, 103:45-51.
49. Rupprecht HJ, Blankenberg S, Bickel C, et al.: Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001, 104:25-31.
50. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al.: Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002, 105:15-21.